OSE OSE Immunotherapeutics SA

OSE Immunotherapeutics annonce l’accord de délivrance d’un brevet en Europe protégeant FR104, immunothérapie first-in-class antagoniste du CD28

OSE Immunotherapeutics annonce l’accord de délivrance d’un brevet en Europe protégeant FR104, immunothérapie first-in-class antagoniste du CD28
FR
12/10/2020

Underlying

OSEOSE Immunotherapeutics SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OSE Immunotherapeutics SA

 PRESS RELEASE
Free
OSE OSE Immunothera...

OSE Immunotherapeutics to Present at Upcoming Investor Conferences

OSE Immunotherapeutics to Present at Upcoming Investor Conferences Nantes, France, March 23, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announces its participation in the following investor conferences: Mardi de la Bourse – Lyon Pôle Bourse (retail event)April 7, 2026 – CRCC Lyon, France Marc Le Bozec, Chief Executive Officer, will present the Company and meet with wealth managers, financial advisors and individual investo...

March 23, 2026 1 EN
 PRESS RELEASE
Free
OSE OSE Immunothera...

OSE Immunotherapeutics invitée à présenter lors des prochaines confére...

OSE Immunotherapeutics invitée à présenter lors des prochaines conférences investisseurs Nantes, France, 23 mars 2026 – 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE), une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie et immuno-inflammation,annonce aujourd’hui sa participation aux conférences investisseurs suivantes : Mardi de la Bourse – Lyon Pôle Bourse7 avril 2026 – CRCC Lyon, France Marc Le Bozec, Directeur Général, présentera la Société et rencontrera des gestionnaires de patrimoine, des conseillers...

March 23, 2026 1 EN
 PRESS RELEASE
Free
OSE OSE Immunothera...

OSE Immunotherapeutics Announces its 2026 Financial Calendar

OSE Immunotherapeutics Announces its 2026 Financial Calendar Nantes, France, March 16, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026.   InformationDate* 2025 Full-Year Financial Update and StatementsApril 29, 20262026 1Q Cash PositionApril 30, 2026Annual General MeetingJune 24, 20262026 First-Half Financial Update and StatementsSeptember 28, 20262026 3Q Cash PositionOctober 27, 20262026 4Q Cash PositionJanuary 26, 2027 * This financial calendar is provided for information only and may be subject to changes. ...

March 16, 2026 1 EN
 PRESS RELEASE
Free
OSE OSE Immunothera...

OSE Immunotherapeutics annonce son calendrier financier pour 2026

OSE Immunotherapeutics annonce son calendrier financier pour 2026 Nantes, France, 16 mars 2026 – 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) annonce aujourd’hui son calendrier financier pour 2026. InformationDate* Résultats financiers annuels 202529 avril 2026Position de trésorerie du 1er trimestre 202630 avril 2026Assemblée Générale des actionnaires24 juin 2026Résultats financiers du 1er semestre 202628 septembre 2026Position de trésorerie du 3ème trimestre 202627 octobre 2026Position de trésorerie du 4ème trimestre 202626 janvier 2027 * Ce calendrier financi...

March 16, 2026 1 EN
 PRESS RELEASE
Free
OSE OSE Immunothera...

OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Offic...

OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth Nantes, France, March 10, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive Officer, effective immediately. Mr. Le Bozec had served as interim CEO since October 2, 2025.   Following a thorough review of internal and external candidates and upon recommendation of the Nomination and Compensation Committee, the Board of Directors unanimously confirmed Marc Le Bozec...

March 10, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch